LastStop is looking for founders and operators to run its brands. You bring the commitment to grow a site. The seven-figure platform behind it is already done.
You join as a founding partner in an established brand with 20+ properties already through launch prep. They sit on HIPAA-compliant hosting and are mostly waiting on domain names. Payment processing, physicians and pharmacy plug in through the group's options or your own.
Founding partners get in at 80–90% below what this would cost to build alone: a seven-figure platform, a ready-made brand, and no platform license fee. For a founding seat, that alone is the deal.
The plan: fill the first LastStop Village with 20 founding sites. We run the first three ourselves. A founding seat is your site in that Village, not the whole company; the terms, including what you own, are set in a written agreement, and we walk through them on a call.
Industry guides put paid-social acquisition for GLP-1 telehealth at roughly $25–$150 per customer by channel. Rimo
Platform: the growth engine makes ads and landing pages per brand, checks them for compliance, and backs paid ads with an organic network of ~2,000 aged accounts. The model plans on $300 per paying patient, well above those benchmarks.
Medvi, a GLP-1 telehealth brand, reported $401M in 2025 sales with two employees and AI tools, per The New York Times. Summary
Platform: Atlas handles carts, follow-ups, triage and drafting with humans approving. Planning model: ~6.5 staff at 1,000 patients versus ~22 conventionally.
In September 2025 FDA sent about 100 cease-and-desist letters and thousands of warnings over misleading drug ads, and named telehealth firms for the first time. Holland & Knight
Platform: ClaimRight scans every page, ad and email before it publishes. It has already audited 300+ brands in this space.
A developer alone costs a median ~$136K/yr before benefits (U.S. BLS). Planning ranges for a scratch-built compliant platform run $200K to $1M+ and 6–18 months. BLS
Platform: already built and owned. Founding partners pay no platform license fee, and their entry is 80–90% below a custom build.
High-risk processors commonly hold 5–10% of sales for about 180 days, and can close accounts quickly. Merchant Cost Consulting
Platform: several high-risk processors live at once through Remi's processing relationships, so one pause doesn't stop revenue.
This is a sample presentation. The model below uses internal and processor-side figures. Each line is paired with a third-party source so you can check it yourself. Where ours is more optimistic than the outside source, we say so.
| Assumption | Our model | Third-party reference | Read |
|---|---|---|---|
| Monthly price | $299 | Compounded semaglutide programs typically $399–$599/mo; brand-name $800–$1,350. Rimo · Hims & Hers averaged $83/mo per subscriber across all products in FY2025. Subscription Insider | Below market |
| Cost to win a paying patient | $300 | $25–$150 per customer by channel (Meta, Google, TikTok). Rimo | Conservative |
| Patients still on program at 12 months | ~28% | 32% of weight-loss GLP-1 patients still on therapy after one year (claims data, 4,255 patients). Prime Therapeutics via Becker's · Some guides report 40–60% dropout in the first 3 months. Rimo | In range · verify |
| Contribution margin | 55% | Compounded semaglutide gross margins 40–60%; tirzepatide 35–55%. Rimo | In range |
| Processor reserve | 10% · 3 mo | 5–10% of sales, commonly held ~180 days. Merchant Cost Consulting | Ours is shorter · verify |
| Lean operations at scale | ~6.5 staff / 1,000 pts | Medvi: $401M 2025 sales with 2 employees. NYT, summarized · Hims & Hers: $2.35B revenue, 2.51M subscribers, $318M adj. EBITDA in FY2025. | Supported |
A longer reserve hold (180 days instead of 3 months) delays when cash comes back. It doesn't change profit, but it would raise the most cash at risk. Have better data? Industry veterans and researchers who can source or challenge any line here are exactly who we want to hear from.
Median of 2,500 simulated runs per budget, from the LastStop simulator. Your budget goes into ads once; the business reinvests its margin. Simulated, not a promise of results. Run it yourself →
It takes one or two strong results in the first 90 days to raise demand. Later partners may face license and infrastructure fees, possibly mid-six figures for limited access. Founding partners won't.
Lit: the first ten founding seats. Blueprint: seats that may be withdrawn if demand surges, and may never be released.
Fresh telemedicine sites on the shared platform.
Move practices from older software onto the platform and the community.
Clinics staffed by physicians who use the same tools.
Your whole budget goes into your own site's advertising. The only extra is a one-time setup fee: + $5K at $50K, + $8K at $100K and + $20K at $200K. It covers your setup and the hookups: payment processors, physician network and pharmacy connections.
So the platform costs you next to nothing. Most of your money funds the same advertising you would need to buy on your own, except here it runs on a seven-figure platform from day one.
I'm looking for sales reps and people who want to help promote a project that's about to launch. What follows is the preliminary sales information. If you have experience selling telemedicine platforms or working with peptides, or can provide grounded research for the numbers here, that would be extremely helpful.
I'm confident in these numbers from inside the high-risk card processing space. But people outside that world deserve outside proof. I want to point to a third party and say "they said it," not "trust me."
A state-of-the-art, seven-figure platform with all the bells and whistles. It's a living platform that improves almost every week, and every foundational partner benefits from each upgrade. The most recent was Atlas AI, added in the last 30 days and given to all partners without a discussion, never mind a price tag.
The 20 initial sites are already built and deployed on HIPAA-compliant hosting. They integrate with multiple pharmacies, multiple physician networks and EHR connections, with feature lists matched against the best competitors in the space. You're not buying into an imaginary process or a code base that still has to go through the motions.
Founding partners become the face of their site. You put down your entry, plus your time and commitment to growing your site. There's no platform license fee, and your whole budget goes into your site's advertising. The only extra is a one-time setup fee: $5K at $50K, $8K at $100K, $20K at $200K. I want a commitment to proactive growth, not a few extra dollars in my bank account.
Preliminary entry is 80–90% below the true cost. Greed isn't driving this. The goal is to grow the brand and build something together with partners willing to take on this adventure with me.
Most new telehealth businesses spend their startup capital on expenses that keep them unprofitable for 6, 12 or 18 months. Here, most of a partner's capital goes back into growth, and the model shows the books turning black within months. How fast depends on the size of the commitment. Real results still have to prove that out.
Newcomers are welcome to start a fresh property, or to move over from a platform that lacks these tools, this support, or a community. We start with new telemedicine brands, move into absorbing existing practices, and eventually reach physical clinics staffed by doctors who benefit from the same tools.
I'm looking for sales, support, partners and owners, and team members who can't contribute financially but will put in time, effort and other resources to earn their place. Above all, the numbers need support. Industry veterans and novices alike: if you'll roll up your sleeves and help with the research, reach out.
Everyone should go in with complete information about what's built, what's pending, and what's still a dream. That's why the full platform site shows and explains virtually every screen.
I'd like to hear from larger players and potential partners in this space too. We're walking the same path and facing the same problems, and there will be far more against us outside our group than within it. I'm happy to offer what we build internally to partners and collaborators to cement relationships. There's no such thing as a direct competitor, only someone building the same tools and running into the same problems. That sounds more like a team than a rivalry. If the other side sees it differently, may the best man or woman win.
We're planning from the first day as if it were the last. Speed is our greatest asset, attention to detail keeps it from becoming a pain point, and the goal is to shock and awe with this year's progress. If anyone doubts that, I kindly ask them to check back in every 30 days.
Remi Soltys, MD
Founder, LastStop OS
Message Remi Soltys, MD on LinkedIn with the role you're interested in and what you'd bring.
LastStop OS · founding partners